{
  "guideline": {
    "id": "PA166219301",
    "name": "Annotation of CPIC Guideline for dexlansoprazole and CYP2C19",
    "source": "CPIC",
    "version": 6,
    "url": "https://www.pharmgkb.org/guidelineAnnotation/PA166219301",
    "relatedChemicals": [
      {
        "id": "PA166110257",
        "name": "dexlansoprazole",
        "symbol": null
      }
    ],
    "relatedGenes": [
      {
        "id": "PA124",
        "name": "cytochrome P450 family 2 subfamily C member 19",
        "symbol": "CYP2C19"
      }
    ],
    "recommendation": true
  },
  "recommendations": [
    {
      "id": "PA166297667",
      "name": "Recommendation PA166297667",
      "population": "general",
      "classification": {
        "term": "Optional",
        "termId": "guidelineStrength:981565059"
      },
      "relatedChemicals": [
        {
          "id": "PA166110257",
          "name": "dexlansoprazole",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452060269,
        "html": "<p>Increase starting daily dose by 100%. Daily dose may be given in divided doses. Monitor for efficacy.</p>\n"
      },
      "implications": [
        "CYP2C19: Decreased plasma concentrations of PPIs compared to CYP2C19 NMs; increased risk of therapeutic failure"
      ],
      "lookupKey": {
        "CYP2C19": "Ultrarapid Metabolizer"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166297672",
      "name": "Recommendation PA166297672",
      "population": "general",
      "classification": {
        "term": "Optional",
        "termId": "guidelineStrength:981565059"
      },
      "relatedChemicals": [
        {
          "id": "PA166110257",
          "name": "dexlansoprazole",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452060274,
        "html": "<p>Initiate standard starting daily dose. For chronic therapy (&gt;12 weeks) and efficacy achieved, consider 50% reduction in daily dose and monitor for continued efficacy.</p>\n"
      },
      "implications": [
        "CYP2C19: Increased plasma concentration of PPI compared to CYP2C19 NMs; increased chance of efficacy and potentially toxicity"
      ],
      "lookupKey": {
        "CYP2C19": "Poor Metabolizer"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166297668",
      "name": "Recommendation PA166297668",
      "population": "general",
      "classification": {
        "term": "Optional",
        "termId": "guidelineStrength:981565059"
      },
      "relatedChemicals": [
        {
          "id": "PA166110257",
          "name": "dexlansoprazole",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452060270,
        "html": "<p>Initiate standard starting daily dose. Consider increasing dose by 50-100% for the treatment of H. pylori infection and erosive esophagitis. Daily dose may be given in divided doses.\nMonitor for efficacy.</p>\n"
      },
      "implications": [
        "CYP2C19: Decreased plasma concentrations of PPIs compared to CYP2C19 NMs; increased risk of therapeutic failure"
      ],
      "lookupKey": {
        "CYP2C19": "Rapid Metabolizer"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166297673",
      "name": "Recommendation PA166297673",
      "population": "general",
      "classification": {
        "term": "No recommendation",
        "termId": "guidelineStrength:1448526251"
      },
      "relatedChemicals": [
        {
          "id": "PA166110257",
          "name": "dexlansoprazole",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452060275,
        "html": "<p>No recommendation</p>\n"
      },
      "implications": [
        "CYP2C19: n/a"
      ],
      "lookupKey": {
        "CYP2C19": "Indeterminate"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166297669",
      "name": "Recommendation PA166297669",
      "population": "general",
      "classification": {
        "term": "Optional",
        "termId": "guidelineStrength:981565059"
      },
      "relatedChemicals": [
        {
          "id": "PA166110257",
          "name": "dexlansoprazole",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452060271,
        "html": "<p>Initiate standard starting daily dose. Consider increasing dose by 50-100% for the treatment of H. pylori infection and erosive esophagitis. Daily dose may be given in divided doses.\nMonitor for efficacy.</p>\n"
      },
      "implications": [
        "CYP2C19: Normal PPI metabolism; may be at increased risk of therapeutic failure compared to CYP2C19 IMs and PMs"
      ],
      "lookupKey": {
        "CYP2C19": "Normal Metabolizer"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166297670",
      "name": "Recommendation PA166297670",
      "population": "general",
      "classification": {
        "term": "Optional",
        "termId": "guidelineStrength:981565059"
      },
      "relatedChemicals": [
        {
          "id": "PA166110257",
          "name": "dexlansoprazole",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452060272,
        "html": "<p>Initiate standard starting daily dose. For chronic therapy (&gt;12 weeks) and efficacy achieved, consider 50% reduction in daily dose and monitor for continued efficacy.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>The strength of recommendation for &quot;likely&quot; phenotypes are the same as their respective confirmed phenotypes. &quot;Likely&quot; indicates the uncertainty in the phenotype assignment, but it is reasonable to apply the recommendation for the confirmed phenotype to the corresponding &quot;likely&quot; phenotype.</p>\n"
      },
      "implications": [
        "CYP2C19: Likely increased plasma concentration of PPI compared to CYP2C19 NMs; likely increased chance of efficacy and potentially toxicity"
      ],
      "lookupKey": {
        "CYP2C19": "Likely Intermediate Metabolizer"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166297644",
      "name": "Recommendation PA166297644",
      "population": "general",
      "classification": {
        "term": "Optional",
        "termId": "guidelineStrength:981565059"
      },
      "relatedChemicals": [
        {
          "id": "PA166110257",
          "name": "dexlansoprazole",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452060246,
        "html": "<p>Initiate standard starting daily dose. For chronic therapy (&gt;12 weeks) and efficacy achieved, consider 50% reduction in daily dose and monitor for continued efficacy.</p>\n"
      },
      "implications": [
        "CYP2C19: Increased plasma concentration of PPI compared to CYP2C19 NMs; increased chance of efficacy and potentially toxicity"
      ],
      "lookupKey": {
        "CYP2C19": "Intermediate Metabolizer"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166297671",
      "name": "Recommendation PA166297671",
      "population": "general",
      "classification": {
        "term": "Optional",
        "termId": "guidelineStrength:981565059"
      },
      "relatedChemicals": [
        {
          "id": "PA166110257",
          "name": "dexlansoprazole",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452060273,
        "html": "<p>Initiate standard starting daily dose. For chronic therapy (&gt;12 weeks) and efficacy achieved, consider 50% reduction in daily dose and monitor for continued efficacy.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>The strength of recommendation for &quot;likely&quot; phenotypes are the same as their respective confirmed phenotypes. &quot;Likely&quot; indicates the uncertainty in the phenotype assignment, but it is reasonable to apply the recommendation for the confirmed phenotype to the corresponding &quot;likely&quot; phenotype.</p>\n"
      },
      "implications": [
        "CYP2C19: Likely increased plasma concentration of PPI compared to CYP2C19 NMs; likely increased chance of efficacy and potentially toxicity"
      ],
      "lookupKey": {
        "CYP2C19": "Likely Poor Metabolizer"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    }
  ],
  "citations": [
    {
      "pmid": "32770672",
      "title": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C19 and Proton Pump Inhibitor Dosing.",
      "authors": [
        "Lima John J",
        "Thomas Cameron D",
        "Barbarino Julia",
        "Desta Zeruesenay",
        "Van Driest Sara L",
        "El Rouby Nihal",
        "Johnson Julie A",
        "Cavallari Larisa H",
        "Shakhnovich Valentina",
        "Thacker David L",
        "Scott Stuart A",
        "Schwab Matthias",
        "Uppugunduri Chakradhara Rao S",
        "Formea Christine M",
        "Franciosi James P",
        "Sangkuhl Katrin",
        "Gaedigk Andrea",
        "Klein Teri E",
        "Gammal Roseann S",
        "Furuta Takahisa"
      ],
      "journal": "Clinical pharmacology and therapeutics",
      "year": 2021
    }
  ],
  "version": "2023-12-19-10-38"
}